Novartis says top French court annulled its antitrust victory in Lucentis case (correct*)
( July 18, 2025, 07:31 GMT | Official Statement) -- MLex Summary: Novartis said it may need to pay an antitrust fine of $443 million after France's top court sided with the French Competition Authority in a landmark case over its Lucentis eyesight treatment. At the heart of the litigation is a 2019 finding that Novartis and Roche abused a dominant position by denigrating or trash-talking a rival, Avastin. A lower-court, which originally upheld Novartis's appeal, has been ordered to re-examine the case. ...
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.